Emily Bodnar’s rating is based to the anticipation of considerable milestones for Agenus in the approaching calendar year, specifically the probable filing of the Biologics License Software (BLA) for his or her guide drug prospect, botensilimab (bot). Agenus has dosed about 900 individuals with bot throughout various sound tumors, exhibiting a de